Revance Therapeutics Inc. buy stratec
Start price
03.10.19
/
50%
€11.30
Target price
04.11.21
€32.00
Performance (%)
7.96%
End price
05.11.21
€12.20
Summary
This prediction ended on 05.11.21 with a price of €12.20. The BUY prediction by stratec finished with a performance of 7.96%. stratec has 50% into this predictionPerformance without dividends (%)
| Name | 1w | 1m | 1y | 3y |
|---|---|---|---|---|
| Revance Therapeutics Inc. | - | - | - | - |
| iShares Core DAX® | -0.543% | 1.491% | 13.638% | 16.760% |
| iShares Nasdaq 100 | -2.696% | -1.235% | 31.879% | 45.155% |
| iShares Nikkei 225® | -2.863% | 2.491% | 12.078% | 7.840% |
| iShares S&P 500 | -1.105% | 0.013% | 26.888% | 43.056% |
Comments by stratec for this prediction
In the thread Revance Therapeutics Inc. diskutieren
Mizuho Securities is maintaining its Buy rating and $34 price target on Revance Therapeutics (RVNC) today. Revance presented at the Well Fargo Health Conference in early September. In late August the company amended its agreement with Mylan (MYL) around extending the target date for the latter to decide whether to continue development and commercialization of a biosimilar to Allergan's (AGN) BOTOX. That same day, Needham maintained its Buy rating and $32 price target on RVNC and had this to say about the amended agreement:
"RVNC issued an 8K this morning announcing an amendment to the collaboration that extends the clock on MYL's opt-in decision to 4/30/2020, in return for a $5MM payment. The additional time should allow MYL and Upjohn to conduct a portfolio review ahead of transaction close expected in mid-2020"
"RVNC issued an 8K this morning announcing an amendment to the collaboration that extends the clock on MYL's opt-in decision to 4/30/2020, in return for a $5MM payment. The additional time should allow MYL and Upjohn to conduct a portfolio review ahead of transaction close expected in mid-2020"
In the thread Trading Revance Therapeutics Inc.
Die von stratec gewählte maximale Laufzeit wurde überschritten